The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Under the Biden administration proposal unveiled last November, an estimated 3.4 million Americans on Medicare would be ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...